ストックスクリーナーアプリを入手
14.37
6.37%
0.86
Arcutis Biotherapeutics Inc (ARQT) 最新ニュース
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ARQT Stock News - GuruFocus
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Arcutis Grants 72,000 Restricted Stock Units to 9 New Hires: Key Details on 4-Year Vesting Plan - Stock Titan
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Arcutis Presents Long-Term INTEGUMENT-OLE Data on Roflumilast at RAD 2025 - Dermatology Times
Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis - Benzinga
Road to RAD: What to Expect - Dermatology Times
ARQT Reveals Promising Long-Term Data for Zoryve in Atopic Derma - GuruFocus
Arcutis says Zoryve data demonstrates durable atopic dermatitis improvements - Seeking Alpha
Where are the Opportunities in (ARQT) - news.stocktradersdaily.com
Arcutis Biotherapeutics director Heron buys $30,246 in stock - Investing.com
Arcutis (ARQT) to Showcase New Data at 2025 RAD Conference | ARQ - GuruFocus
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast - GuruFocus
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference - The Manila Times
New Clinical Data: ZORYVE's Breakthrough 34-Week Skin Control for Children with Atopic Dermatitis - Stock Titan
Two Sigma Investments LP Cuts Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Arcutis Biotherapeutics: Navigating Commercialization With Promising Upside - Seeking Alpha
H.C. Wainwright reiterates buy rating and $19 target on Arcutis stock - Investing.com
Transcript : Arcutis Biotherapeutics, Inc.Shareholder/Analyst Call - marketscreener.com
Nuveen Asset Management LLC Has $5.11 Million Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 5% – Time to Sell? - Defense World
Possible Bearish Signals With Arcutis Biotherapeutics Insiders Disposing Stock - simplywall.st
Ameriprise Financial Inc. Acquires 50,662 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Arcutis Biotherapeutics SVP sells $24,806 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics SVP sells $24,806 in stock - Investing.com Australia
Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Immuno-Dermatology Leader Arcutis Set for Key Goldman Sachs Healthcare Conference Presentation - Stock Titan
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by Bank of America Corp DE - Defense World
Needham & Company LLC Reaffirms Buy Rating for Arcutis Biotherapeutics (NASDAQ:ARQT) - Defense World
Arcutis wins FDA nod for Zoryve foam for plaque psoriasis - MSN
Analyst Expectations For Arcutis Biotherapeutics's Future - Benzinga
ARQT Analyst Reiterates Buy Rating with $20 Price Target | ARQT Stock News - GuruFocus
Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older - BioSpace
FDA approves roflumilast foam 0.3% for scalp, body psoriasis - Contemporary Pediatrics
FDA approves ZORYVE foam for plaque psoriasis treatment - Investing.com Australia
FDA Approves Arcutis' (ARQT) Zoryve Foam for Psoriasis Treatment - GuruFocus
Arcutis Biotherapeutics' Foam Psoriasis Treatment Gets FDA Approval - marketscreener.com
FDA Approval Boosts Arcutis Biotherapeutics (ARQT) with New Psor - GuruFocus
Arcutis wins FDA nod for Zoryve foam in psoriasis (ARQT:NASDAQ) - Seeking Alpha
Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older | ARQT Stock News - GuruFocus
FDA approves ZORYVE foam for plaque psoriasis treatment By Investing.com - Investing.com India
Understanding Roflumilast Foam's FDA Approval for Scalp and Body Psoriasis, with Jennifer Soung, MD - HCPLive
Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older - The Manila Times
Better Weight Loss Stock: Amgen or Viking Therapeutics? - The Globe and Mail
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
79,815 Shares in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Acquired by BNP Paribas Financial Markets - Defense World
The Manufacturers Life Insurance Company Sells 1,547 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
When the Price of (ARQT) Talks, People Listen - news.stocktradersdaily.com
ARQT: Key Insights from Genital Psoriasis Consensus Statements | - GuruFocus
New Consensus Statements on Impact of Genital Psoriasis on Patie - GuruFocus
Northern Trust Corp Acquires 54,541 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice - The Manila Times
Arcutis Biotherapeutics Publishes Expert Consensus on Genital Psoriasis to Enhance Patient Care and Treatment Decision-Making - Nasdaq
Medical Breakthrough: Experts Release 14 Game-Changing Guidelines for Genital Psoriasis Treatment - Stock Titan
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):